Prostate-specific antigen has proven to be a new useful marker for the evaluation of men with prostatic cancer. In addition to its proven value for immunohistochemical staining and for the followup evaluation of men treated with hormonal therapy, the monoclonal immunoradiometric assay for PSA has proven to be a unique, sensitive, and specific marker for the followup evaluation of men who have undergone radical prostatectomy.